Showing 4071-4080 of 9153 results for "".
- Sclerotic cGVHD Patients Show Higher Risk for Outcome Reporting Mismatchhttps://practicaldermatology.com/news/patient-reported-cgvhd-worsening-linked-to-mortality-in-sclerotic-disease/2485447/A new longitudinal cohort study published in JAMA Dermatology showed differences in frequency and importance of discordance between clinician-reported and patient-reported outcomes in cutaneous chronic graft-vs-host disease (cG
- Analysis: Chronic Hand Eczema Affects 1 in 10 Adultshttps://practicaldermatology.com/news/chronic-hand-eczema-affects-1-in-10-adults-study-finds/2485383/A cross-sectional study of over 10,000 U.S. adults indicates chronic hand eczema (CHE) is more common than previously estimated, with nearly 1 in 10 reporting a physician diagnosis. The data, presented in a poster by Raj Chovati
- TYK2 Inhibitor Envudeucitinib Shows Durable Skin Clearance, QoL Gains: Posterhttps://practicaldermatology.com/news/tyk2-inhibitor-envudeucitinib-shows-durable-skin-clearance-qol-gains-poster/2485378/Envudeucitinib, an investigational selective allosteric TYK2 inhibitor, showed sustained achievement of clinically meaningful treat-to-target outcomes in patients with moderate-to-severe plaque psoriasis, according to 52-week data presented at 2026 Winter Clinical
- Dr. James Del Rosso Presents ‘Medicine Chest’ at Winter Clinical 2026https://practicaldermatology.com/news/dr-james-del-rosso-presents-medicine-chest-at-winter-clinical-2026/2485373/James Q. Del Rosso, DO, delivered his annual “What’s New in the Medicine Chest” update at the 2026 Winter Clinical Dermatology Conference, covering new therapies, novel data, and practice-changing pearls spanning from molluscum and hyperhidrosis to vitiligo, lichen planus, and even mastocytosis.<
- Dr. Darrell Rigel Highlights Urgent Skin Cancer Trends at Winter Clinical 2026https://practicaldermatology.com/news/dr-darrell-rigel-highlights-urgent-skin-cancer-trends-at-winter-clinical-2026/2485361/Skin cancer continues its upward trajectory, with new data showing that one in 19 Americans will be diagnosed with melanoma in their lifetime. This alarming statistic headlined a wide-ranging presentation by Darrell S. Rigel, MD, MS, at the 2026 Winter Clinical Dermatology Conference in Hawaii, w
- Vitiligo Linked to Elevated Risk of Herpes Zoster: Cohort Studyhttps://practicaldermatology.com/news/vitiligo-linked-to-elevated-risk-of-herpes-zoster-study-finds/2485328/A new cohort study from Taiwan indicated vitiligo is independently associated with a heightened risk of herpes zoster (HZ), with systemic immunosuppressive therapies compounding the risk further. Using data from Taiwan's Longit
- TOGETHER-PsA: Weight Loss Plus PsA Control with Ixekizumab and Tirzepatidehttps://practicaldermatology.com/news/together-psa-weight-loss-plus-psa-control-with-ixekizumab-and-tirzepatide/2485259/In the phase 3b TOGETHER-PsA trial, ixekizumab (Taltz, Eli Lilly) used in combination with tirzepatide (Zepbound, Eli Lilly) was more effective than ixekizumab monotherapy in adults with active psoriatic arthritis (PsA) who also have obesity or are overweight with a
- Commentary Flags Risks in Minoxidil Use Among Older Adultshttps://practicaldermatology.com/news/commentary-flags-risks-in-minoxidil-use-among-older-adults/2485231/In a recent commentary published in the Journal of the American Academy of Dermatology, Funda Datli Yakaryilmaz, MD, and Dursun Turkmen, MD, raise concerns about safety monitoring for low-dose oral minoxidil (LDOM) in older
- Review: Wide Variability in Dermatology ICD Code Validityhttps://practicaldermatology.com/news/review-wide-variability-in-dermatology-icd-code-validity/2485230/A systematic review published in JAMA Dermatology showed wide variability in the accuracy of International Classification of Diseases (ICD) codes used to identify dermatologic conditions in U.S. administrative datasets.
- MEK Inhibition Shows Promise in Aggressive EB-Linked Skin Cancershttps://practicaldermatology.com/news/mek-inhibition-shows-promise-in-aggressive-eb-linked-skin-cancers/2485197/A transcriptome-driven drug repurposing strategy has identified selumetinib as a potential therapeutic candidate for aggressive squamous cell carcinomas (SCCs) arising in recessive dystrophic epidermolysis bullosa (RDEB). Resea